Iron deficiency, elevated erythropoietin, fibroblast growth factor 23, and mortality in the general population of the Netherlands: A cohort study.

ABSTRACT:

Background

Emerging data in chronic kidney disease (CKD) patients suggest that iron deficiency and higher circulating levels of erythropoietin (EPO) stimulate the expression and concomitant cleavage of the osteocyte-derived, phosphate-regulating hormone fibroblast growth factor 23 (FGF23), a risk factor for premature mortality. To date, clinical implications of iron deficiency and high EPO levels in the general population, and the potential downstream role of FGF23, are unclear. Therefore, we aimed to determine the associations between iron deficiency and higher EPO levels with mortality, and the potential mediating role of FGF23, in a cohort of community-dwelling subjects.

Methods and findings

We analyzed 6,544 community-dwelling subjects (age 53 ± 12 years; 50% males) who

SUBMITTER: Eisenga MF 

PROVIDER: S-EPMC6553711 | biostudies-literature | 2019 Jun

REPOSITORIES: biostudies-literature